Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06032208

An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL

Led by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Updated on 2026-05-04

100

Participants Needed

4

Research Sites

147 weeks

Total Duration

On this page

Sponsors

L

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Lead Sponsor

B

Baxter Healthcare Corporation

Collaborating Sponsor

AI-Summary

What this Trial Is About

Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL," an application based platform where patients self-report their symptoms with one to three hemodialysis treatments per week for 28 weeks. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of toxins in their blood.

CONDITIONS

Official Title

An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Conventional thrice weekly HD schedule
  • Must be on chronic hemodialysis for at least 3 months
  • Age 2518 years
  • Willing and able to give informed consent
Not Eligible

You will not qualify if you...

  • Active infection (may enroll once infection is cleared)
  • Patients receiving daily hemodialysis treatment
  • Patients currently receiving Hemodiafiltration (HDF), Hemofiltration (HF) or Isolated ultrafiltration (ISO UF) more than once in three months
  • Visual impairment
  • History of neurocognitive impairment
  • History of stroke (CVA)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Seven Oaks Hospital Chronic Disease Innovation Centre Inc. (CDIC)

Winnipeg, Manitoba, Canada, R2V 3M3

Actively Recruiting

2

QEII Health Sciences Centre, Nova Scotia Health

Halifax, Nova Scotia, Canada, B3H 1V7

Actively Recruiting

3

Victoria Hospital, London Health Sciences Centre

London, Ontario, Canada, N6A 5W9

Actively Recruiting

4

Westmount Kidney Care Centre

London, Ontario, Canada, N6K 1M6

Actively Recruiting

Loading map...

Research Team

C

Christopher McIntyre, MBBS DM

CONTACT

J

Jarrin Penny, PHD RN CNeph

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here